Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes
Interventions: Web-based Simulation Tool; Other
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes
Interventions: Omnipod Horizon™ Automated Glucose Control System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Santa Barbara, California • Denver, Colorado • Atlanta, Georgia + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Tandem t:slim X2 with HCL or PLGS; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 65 Years and older
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Orlando, Florida • Rochester, Minnesota • Syracuse, New York + 1 more

Conditions: Type 1 Diabetes
Interventions: iHERO Toolkit Resource; Behavioral
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Los Angeles, California • Gainesville, Florida • Cleveland, Ohio + 1 more

Conditions: Type 1 Diabetes
Interventions: Bi-homonal Bionic Pancreas, Usual care; Device · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypoglycemia, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 20 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 1 Diabetes, Pregnancy, High Risk, Insulin Dependent Diabetes, Pregnancy Related
Interventions: Commercial AID system, Open source AID system; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type 1 Diabetes Mellitus With Hypoglycemia
Interventions: DailyDose Smart Snack app, Dexcom G6 CGM; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 1
Interventions: Gan & Lee Insulin Glargine Injection, Lantus®; Biological
Lead sponsor: Gan and Lee Pharmaceuticals, USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Birmingham, Alabama • Fresno, California • Newport Beach, California + 41 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: GlucoWatch® G2™ Biographer (GW2B), Continuous Glucose Monitoring System™ (CGMS); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 6
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Closed-loop Insulin Pump therapy, Standard Insulin Pump Therapy; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 7 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type I
Interventions: Real-time glucose sensor; Device
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 3 Months to 3 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes Mellitus
Interventions: Continuous Glucose Sensor, Standard Care, CGS + Behavior Therapy; Device · Other · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 16 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type1 Diabetes Mellitus
Interventions: Continuous Glucose Monitor (CGM)+Decision Support System (DSS), Continuous Glucose Monitor (CGM) alone; Device · Other
Lead sponsor: University of Virginia; Other
Eligibility: 15 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Stanford, California • New York, New York • Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 1 Diabetes, Cardiovascular Diseases (CVD), Severe Albuminuria, Estimated Glomerular Filtration Rate (eGFR), Hypoglycemia (Diabetic), Vascular Calcification, Carotid-femoral Pulse Wave Velocity, Kidney Diseases
Interventions: Routine/prescribed exogenous insulin dose; Drug
Lead sponsor: Rachel Miller; Other
Eligibility: Not listed
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Uveal Melanoma, Liver Metastases
Interventions: CVA21, Ipilimumab; Biological
Lead sponsor: Viralytics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Miami Beach, Florida • Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection; Drug · Device
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Hypo-Hyper Minimizer (HHM) System; Device
Lead sponsor: Animas Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 2
States / cities: Santa Barbara, California • Charlottesville, Virginia

Conditions: Diabetes Mellitus, Type 1
Interventions: teplizumab 1 mg/mL; Drug
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 8
States / cities: Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more

Conditions: Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: Libre 2.0 CGM in patients taking subcutaneous insulin with concomitant high dose glucocorticoids; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diabetes, Type 1 Diabetes
Interventions: Daily feedback, Financial incentive; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 20 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 47
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Concord, California + 43 more

Conditions: Type 1 Diabetes
Interventions: Closed loop, Home glucose monitoring, Insulin pump, Continuous glucose monitor; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 6 Years to 45 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 5
States / cities: Stanford, California • Aurora, Colorado • New Haven, Connecticut + 2 more

Search by objective public record fields.

Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)

iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes

Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas

Hippocampal Metabolism and Function in Patients With Type 1 Diabetes

Commercial or Open Source Closed Loop Impact on Pregnancy Study

DailyDose Smart Snack Study for T1D on MDI

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Pilot Study of the GlucoWatch G2 Biographer for the Management of Type 1 Diabetes in Children

Closed-Loop Insulin Delivery in Children Less Than 7 Years of Age

The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children

Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

Collection of Breath and Sweat to Identify Indicators of Hypoglycemia

Relationship Between Insulin Dose and Complications in Type 1 Diabetes

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

CGM Utilization With IV Insulin EndoTool and Subcutaneous Insulin in the Neuro ICU

Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults

The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes